New monoclonal antibodies detect all immunoglobulin free light chains in urine samples from over 13,000 patients

J. Campbell, J. Heaney, Y. Wang, M. Cobbold, M. Goodall, T. Plant, M. Drayson

Research output: Contribution to journalMeeting abstract

Abstract

A decade or so ago, the first automated assay was launched for the quantitation of serum κ and λ immunoglobulin free light chains (FLC). FLC measurement is now a fundamental procedure in the diagnosis and monitoring of patients with plasma cell dyscrasias including multiple myeloma and related subtypes including lightchain- only, oligosecretory and non-secretory myeloma. Despite these advances, the assay, which uses sheep polyclonal anti-human FLC antibodies, has a number of well-observed limitations. It has been proposed that monoclonal antibodies (mAbs) may overcome these limitations. The development of FLC specific mAbs is difficult because the mAbs must demonstrate specificity for epitopes that are exposed on FLC but hidden on LC bound to whole immunoglobulin. This is complicated by the paucity of constant domain epitopes available; which can be further reduced by polymerisation of FLC, particularly FLC λ, thus reducing the number of potential binding sites. Production of mAbs specific for FLC has been described previously but other groups have either found that their mAbs did not detect FLC from all neoplastic plasma cell clones tested, or, have not tested sufficient clones to be confident that the mAbs would detect the FLC from 100% of neoplastic clones. Hence, the purpose of this study was to prospectively assess the clinical utility of new highly-specific mouse anti-human FLC mAbs on a large number of consecutive patient samples. Anti-κ and anti-λ FLC mAbs were covalently coupled to different polystyrene Xmap® beads and assayed, simultaneously, in a multi-plex format by Luminex® (mAb assay). The mAbs displayed no cross-reactivity to bound LC, the alternate LC type, or other human proteins and had improved sensitivity (
LanguageEnglish
Pages16
Number of pages1
JournalClinical Chemistry
Volume60
Issue number10
StatusPublished - 1 Jan 2014

Fingerprint

Immunoglobulin Light Chains
Immunoglobulins
Monoclonal Antibodies
Urine
Light
Assays
Clone Cells
Epitopes
Clone cells
Paraproteinemias
Plasmas
Polystyrenes
Physiologic Monitoring
Plasma Cells
Multiple Myeloma
Polymerization
Sheep
Binding Sites

Keywords

  • monoclonal antibody
  • immunoglobulin
  • epitope
  • antibody
  • paraprotein
  • polystyrene
  • protein
  • Bence Jones protein
  • antigen
  • light chain
  • urinalysis
  • patient
  • human
  • American
  • clinical chemistry
  • assay
  • clone
  • plasma cell
  • gold standard
  • cell clone
  • sheep
  • myeloma
  • multiple myeloma
  • mouse
  • plasma cell dyscrasia
  • monitoring
  • binding site
  • diagnosis
  • cross reaction
  • urine
  • polymerization
  • densitometry
  • electrophoresis
  • competitive inhibition
  • procedures
  • serum

Cite this

Campbell, J., Heaney, J., Wang, Y., Cobbold, M., Goodall, M., Plant, T., & Drayson, M. (2014). New monoclonal antibodies detect all immunoglobulin free light chains in urine samples from over 13,000 patients. Clinical Chemistry, 60(10), 16.

New monoclonal antibodies detect all immunoglobulin free light chains in urine samples from over 13,000 patients. / Campbell, J.; Heaney, J.; Wang, Y.; Cobbold, M.; Goodall, M.; Plant, T.; Drayson, M.

In: Clinical Chemistry, Vol. 60, No. 10, 01.01.2014, p. 16.

Research output: Contribution to journalMeeting abstract

Campbell, J, Heaney, J, Wang, Y, Cobbold, M, Goodall, M, Plant, T & Drayson, M 2014, 'New monoclonal antibodies detect all immunoglobulin free light chains in urine samples from over 13,000 patients', Clinical Chemistry, vol. 60, no. 10, pp. 16.
Campbell, J. ; Heaney, J. ; Wang, Y. ; Cobbold, M. ; Goodall, M. ; Plant, T. ; Drayson, M. / New monoclonal antibodies detect all immunoglobulin free light chains in urine samples from over 13,000 patients. In: Clinical Chemistry. 2014 ; Vol. 60, No. 10. pp. 16.
@article{6bbe7a613cd64462a09cb8fe0c825c5c,
title = "New monoclonal antibodies detect all immunoglobulin free light chains in urine samples from over 13,000 patients",
abstract = "A decade or so ago, the first automated assay was launched for the quantitation of serum κ and λ immunoglobulin free light chains (FLC). FLC measurement is now a fundamental procedure in the diagnosis and monitoring of patients with plasma cell dyscrasias including multiple myeloma and related subtypes including lightchain- only, oligosecretory and non-secretory myeloma. Despite these advances, the assay, which uses sheep polyclonal anti-human FLC antibodies, has a number of well-observed limitations. It has been proposed that monoclonal antibodies (mAbs) may overcome these limitations. The development of FLC specific mAbs is difficult because the mAbs must demonstrate specificity for epitopes that are exposed on FLC but hidden on LC bound to whole immunoglobulin. This is complicated by the paucity of constant domain epitopes available; which can be further reduced by polymerisation of FLC, particularly FLC λ, thus reducing the number of potential binding sites. Production of mAbs specific for FLC has been described previously but other groups have either found that their mAbs did not detect FLC from all neoplastic plasma cell clones tested, or, have not tested sufficient clones to be confident that the mAbs would detect the FLC from 100{\%} of neoplastic clones. Hence, the purpose of this study was to prospectively assess the clinical utility of new highly-specific mouse anti-human FLC mAbs on a large number of consecutive patient samples. Anti-κ and anti-λ FLC mAbs were covalently coupled to different polystyrene Xmap{\circledR} beads and assayed, simultaneously, in a multi-plex format by Luminex{\circledR} (mAb assay). The mAbs displayed no cross-reactivity to bound LC, the alternate LC type, or other human proteins and had improved sensitivity (",
keywords = "monoclonal antibody, immunoglobulin, epitope, antibody, paraprotein, polystyrene, protein, Bence Jones protein, antigen, light chain, urinalysis, patient, human, American, clinical chemistry, assay, clone, plasma cell, gold standard, cell clone, sheep, myeloma, multiple myeloma, mouse, plasma cell dyscrasia, monitoring, binding site, diagnosis, cross reaction, urine, polymerization, densitometry, electrophoresis, competitive inhibition, procedures, serum",
author = "J. Campbell and J. Heaney and Y. Wang and M. Cobbold and M. Goodall and T. Plant and M. Drayson",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "60",
pages = "16",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "10",

}

TY - JOUR

T1 - New monoclonal antibodies detect all immunoglobulin free light chains in urine samples from over 13,000 patients

AU - Campbell, J.

AU - Heaney, J.

AU - Wang, Y.

AU - Cobbold, M.

AU - Goodall, M.

AU - Plant, T.

AU - Drayson, M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - A decade or so ago, the first automated assay was launched for the quantitation of serum κ and λ immunoglobulin free light chains (FLC). FLC measurement is now a fundamental procedure in the diagnosis and monitoring of patients with plasma cell dyscrasias including multiple myeloma and related subtypes including lightchain- only, oligosecretory and non-secretory myeloma. Despite these advances, the assay, which uses sheep polyclonal anti-human FLC antibodies, has a number of well-observed limitations. It has been proposed that monoclonal antibodies (mAbs) may overcome these limitations. The development of FLC specific mAbs is difficult because the mAbs must demonstrate specificity for epitopes that are exposed on FLC but hidden on LC bound to whole immunoglobulin. This is complicated by the paucity of constant domain epitopes available; which can be further reduced by polymerisation of FLC, particularly FLC λ, thus reducing the number of potential binding sites. Production of mAbs specific for FLC has been described previously but other groups have either found that their mAbs did not detect FLC from all neoplastic plasma cell clones tested, or, have not tested sufficient clones to be confident that the mAbs would detect the FLC from 100% of neoplastic clones. Hence, the purpose of this study was to prospectively assess the clinical utility of new highly-specific mouse anti-human FLC mAbs on a large number of consecutive patient samples. Anti-κ and anti-λ FLC mAbs were covalently coupled to different polystyrene Xmap® beads and assayed, simultaneously, in a multi-plex format by Luminex® (mAb assay). The mAbs displayed no cross-reactivity to bound LC, the alternate LC type, or other human proteins and had improved sensitivity (

AB - A decade or so ago, the first automated assay was launched for the quantitation of serum κ and λ immunoglobulin free light chains (FLC). FLC measurement is now a fundamental procedure in the diagnosis and monitoring of patients with plasma cell dyscrasias including multiple myeloma and related subtypes including lightchain- only, oligosecretory and non-secretory myeloma. Despite these advances, the assay, which uses sheep polyclonal anti-human FLC antibodies, has a number of well-observed limitations. It has been proposed that monoclonal antibodies (mAbs) may overcome these limitations. The development of FLC specific mAbs is difficult because the mAbs must demonstrate specificity for epitopes that are exposed on FLC but hidden on LC bound to whole immunoglobulin. This is complicated by the paucity of constant domain epitopes available; which can be further reduced by polymerisation of FLC, particularly FLC λ, thus reducing the number of potential binding sites. Production of mAbs specific for FLC has been described previously but other groups have either found that their mAbs did not detect FLC from all neoplastic plasma cell clones tested, or, have not tested sufficient clones to be confident that the mAbs would detect the FLC from 100% of neoplastic clones. Hence, the purpose of this study was to prospectively assess the clinical utility of new highly-specific mouse anti-human FLC mAbs on a large number of consecutive patient samples. Anti-κ and anti-λ FLC mAbs were covalently coupled to different polystyrene Xmap® beads and assayed, simultaneously, in a multi-plex format by Luminex® (mAb assay). The mAbs displayed no cross-reactivity to bound LC, the alternate LC type, or other human proteins and had improved sensitivity (

KW - monoclonal antibody

KW - immunoglobulin

KW - epitope

KW - antibody

KW - paraprotein

KW - polystyrene

KW - protein

KW - Bence Jones protein

KW - antigen

KW - light chain

KW - urinalysis

KW - patient

KW - human

KW - American

KW - clinical chemistry

KW - assay

KW - clone

KW - plasma cell

KW - gold standard

KW - cell clone

KW - sheep

KW - myeloma

KW - multiple myeloma

KW - mouse

KW - plasma cell dyscrasia

KW - monitoring

KW - binding site

KW - diagnosis

KW - cross reaction

KW - urine

KW - polymerization

KW - densitometry

KW - electrophoresis

KW - competitive inhibition

KW - procedures

KW - serum

M3 - Meeting abstract

VL - 60

SP - 16

JO - Clinical Chemistry

T2 - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 10

ER -